RUCAPARIB

N/A

Manufactured by pharmaand GmbH

29,211 FDA adverse event reports analyzed

Last updated: 2026-04-14

About RUCAPARIB

RUCAPARIB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by pharmaand GmbH. The most commonly reported adverse reactions for RUCAPARIB include FATIGUE, NAUSEA, MALIGNANT NEOPLASM PROGRESSION, DECREASED APPETITE, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RUCAPARIB.

Top Adverse Reactions

FATIGUE2,540 reports
NAUSEA2,254 reports
MALIGNANT NEOPLASM PROGRESSION1,182 reports
DECREASED APPETITE799 reports
DIARRHOEA787 reports
CONSTIPATION781 reports
VOMITING780 reports
ASTHENIA675 reports
ADVERSE EVENT571 reports
CARBOHYDRATE ANTIGEN 125 INCREASED569 reports
DYSGEUSIA565 reports
ANAEMIA549 reports
PRODUCT DOSE OMISSION ISSUE546 reports
PLATELET COUNT DECREASED538 reports
DRUG INEFFECTIVE516 reports
HEADACHE436 reports
DIZZINESS406 reports
MALAISE406 reports
DYSPNOEA397 reports
ABDOMINAL PAIN387 reports
ABDOMINAL PAIN UPPER366 reports
PRODUCT DOSE OMISSION362 reports
HAEMOGLOBIN DECREASED359 reports
DEATH349 reports
ABDOMINAL DISCOMFORT348 reports
WHITE BLOOD CELL COUNT DECREASED315 reports
WEIGHT DECREASED295 reports
PAIN294 reports
RED BLOOD CELL COUNT DECREASED288 reports
DRUG INTOLERANCE272 reports
TASTE DISORDER271 reports
BLOOD CREATININE INCREASED266 reports
OFF LABEL USE265 reports
INSOMNIA262 reports
PRURITUS262 reports
TUMOUR MARKER INCREASED259 reports
PRODUCT USE IN UNAPPROVED INDICATION233 reports
NEUROPATHY PERIPHERAL232 reports
UNDERDOSE232 reports
ARTHRALGIA230 reports
ABDOMINAL DISTENSION217 reports
DRUG DOSE OMISSION217 reports
BLOOD COUNT ABNORMAL197 reports
DEHYDRATION197 reports
RASH194 reports
BACK PAIN192 reports
THROMBOCYTOPENIA189 reports
PERIPHERAL SWELLING182 reports
HEPATIC ENZYME INCREASED180 reports
COUGH178 reports
PAIN IN EXTREMITY178 reports
FEELING ABNORMAL172 reports
LABORATORY TEST ABNORMAL170 reports
PHOTOSENSITIVITY REACTION170 reports
ANXIETY163 reports
OVARIAN CANCER RECURRENT163 reports
TOXICITY TO VARIOUS AGENTS162 reports
URINARY TRACT INFECTION162 reports
SOMNOLENCE158 reports
DYSPEPSIA156 reports
PRESCRIBED UNDERDOSE156 reports
ALOPECIA151 reports
PYREXIA145 reports
DEPRESSION144 reports
LIVER FUNCTION TEST INCREASED140 reports
ALANINE AMINOTRANSFERASE INCREASED137 reports
GAIT DISTURBANCE137 reports
THERAPY PARTIAL RESPONDER136 reports
STOMATITIS128 reports
ASPARTATE AMINOTRANSFERASE INCREASED127 reports
FLATULENCE126 reports
NASOPHARYNGITIS122 reports
DRY MOUTH113 reports
FALL111 reports
MYALGIA110 reports
PRODUCT DOSE OMISSION IN ERROR110 reports
RENAL FUNCTION TEST ABNORMAL108 reports
ACCIDENTAL UNDERDOSE106 reports
DRY SKIN101 reports
NEUTROPENIA100 reports
RENAL IMPAIRMENT94 reports
INTESTINAL OBSTRUCTION91 reports
PNEUMONIA89 reports
BLOOD PRESSURE INCREASED88 reports
MUSCLE SPASMS88 reports
BLOOD MAGNESIUM DECREASED86 reports
MUSCULAR WEAKNESS86 reports
HYPOAESTHESIA85 reports
PARAESTHESIA85 reports
HYPOPHAGIA84 reports
WEIGHT INCREASED83 reports
TREMOR82 reports
GASTROOESOPHAGEAL REFLUX DISEASE80 reports
HOT FLUSH79 reports
CONTUSION78 reports
MEMORY IMPAIRMENT78 reports
SUNBURN78 reports
RENAL DISORDER77 reports
BONE PAIN76 reports
HYPERTENSION75 reports

Report Outcomes

Out of 8,726 classified reports for RUCAPARIB:

Serious 43.1%Non-Serious 56.9%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female7,768 (92.8%)
Male603 (7.2%)
Unknown2 (0.0%)

Reports by Age

Age 70144 reports
Age 71133 reports
Age 66131 reports
Age 62128 reports
Age 69128 reports
Age 61124 reports
Age 63122 reports
Age 72121 reports
Age 67120 reports
Age 60119 reports
Age 64118 reports
Age 76116 reports
Age 68113 reports
Age 65112 reports
Age 56104 reports
Age 75102 reports
Age 7399 reports
Age 5997 reports
Age 5891 reports
Age 7490 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with RUCAPARIB?

This profile reflects 29,211 FDA FAERS reports that mention RUCAPARIB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for RUCAPARIB?

Frequently reported terms in FAERS include FATIGUE, NAUSEA, MALIGNANT NEOPLASM PROGRESSION, DECREASED APPETITE, DIARRHOEA, CONSTIPATION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures RUCAPARIB?

Labeling and FAERS entries often list pharmaand GmbH in connection with RUCAPARIB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.